Episodic Kinesigenic Dyskinesia 3 C5830280
A genetic movement disorder causing episodic involuntary movements triggered by sudden motion. Typically responds well to medication.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Paroxysmal dyskinesia
(neurologic)Tonic-clonic movements
(neurologic)Hemiballismus
(neurologic)Walking difficulties
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Primary Pharmacological Management
Carbamazepine remains the most studied and effective medication for episodic kinesigenic dyskinesia type 3, significantly reducing episode frequency in most patients.
Environmental Modifications
Modifying living and work environments to reduce sudden environmental changes, obstacles, and situations requiring rapid movement responses.
Additional treatment options
Calcium Channel Modulators
Some patients respond to calcium channel antagonists such as flunarizine, which may help regulate neuronal excitability in this channelopathy.
medicationCoordination and Balance Training
Physical therapy programs focused on improving coordination, balance, and controlled movement patterns can enhance safety and confidence during daily activities.
physical_therapyEpisode Diary and Trigger Mapping
Maintaining a detailed diary of episodes, circumstances, and potential triggers helps identify patterns and guides treatment adjustments.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Episodic Kinesigenic Dyskinesia 3 C5830280?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chen J, Li R, Zhang Y. Paroxysmal dyskinesias: Update on genetics and clinical management. Mov Disord Clin Pract. 2022.
Bhatia KP, Fasano A, Berardelli A. International guidelines for the treatment of paroxysmal movement disorders. Neurology. 2021.
Liu Q, Wang X, Chen J. Clinical features and treatment outcomes of episodic kinesigenic dyskinesia: A prospective cohort study. Neurology. 2020.
Huang YG, Yang Q, Chen X. Episodic kinesigenic dyskinesia: From phenotype to genotype and management strategies. Orphanet J Rare Dis. 2023.
Medication Comparisons
Compare medications used to treat Episodic Kinesigenic Dyskinesia 3 C5830280. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy